A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.8K citations · Full text

Medicine, Neurology, Oncology +15

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Mark R. Gilbert, James J. Dignam, Terri S. Armstrong et al. · New England Journal of Medicine · 2014 · 2.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

Teri Kreisl, Lyndon Kim, Paul Duic et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Mark R. Gilbert, Meihua Wang, Kenneth Aldape et al. · Journal of Clinical Oncology · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17